FDA approves Cobas EZH2 Mutation Test as CDx

Create PDF

July 7, 2020—The Food and Drug Administration approved the Roche Cobas EZH2 Mutation Test as a companion diagnostic for Tazverik (tazemetostat), developed by Epizyme. This molecular test detects abnormalities in the EZH2, or enhancer of zeste homolog 2, gene in patients with follicular lymphoma. It is expected to be available in the Unites States later this year.